Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.
Clinical trial NCT06992609 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06992609
- Sponsor
- AstraZeneca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-09-15
- Primary completion
- 2029-06-30
- Enrollment
- 68
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.